Psilocin as a Broad Inhibitor of CYP450 Enzymes: Integrated In Vitro and In Silico Evidence
Diana Silva, Andreia Machado Brito-Da-Costa, Mariana Carvalho, Ricardo Jorge Dinis-Oliveira, Áurea Madureira-Carvalho, Sérgio F. Sousa
Instituto Politécnico do Porto February 25, 2026 DOI: 10.26537/prpaeh.v4i3.7159 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | In vitro and in silico study Peer reviewed |
|---|---|
| Interventions | Psilocybin Psilocin |
| Measures | IC50, MM/GBSA binding free energy, per-residue energy decomposition, hydrogen bond analysis |
| Topics | Psilocybin |
| Key points | Psilocin inhibited all five tested human CYP450 isoenzymes, with IC50 values of 2.06 µM (CYP2A6), 6.17 µM (CYP2B6), 11.89 µM (CYP2D6), 6.37 µM (CYP2E1), and 2.36 µM (CYP3A4). The authors conclude that psilocin is a relevant inhibitor of multiple CYP450 enzymes, particularly CYP2A6 and CYP3A4, indicating a potential risk of metabolic drug-drug interactions. |
Abstract
Background: Psilocybin is a psychoactive compound found in hallucinogenic mushrooms and is rapidly dephosphorylated in vivo to psilocin, its pharmacologically active metabolite. Despite the growing clinical and scientific interest in these substances, information regarding their interaction with cytochrome P450 (CYP450) enzymes remains scarce, raising concerns about potential drug–drug interactions.
Objective: To evaluate, using combined in vitro and in silico approaches, the inhibitory potential of psilocybin and psilocin toward the human CYP2A6, CYP2B6, CYP2D6, CYP2E1, and CYP3A4 isoenzymes.
Methods: Enzyme inhibition was assessed in vitro using fluorometric assays based on Vivid® substrates and recombinant human CYP enzymes expressed in baculosomes. Half-maximal inhibitory concentration (IC₅₀) values were calculated. In silico analyses comprised molecular dynamics simulations performed with the PMEMD.cuda module of AMBER16, followed by MM/GBSA binding free energy calculations, per-residue energy decomposition, and hydrogen bond analysis over the final 100 ns of stabilized trajectories.
Results: Psilocin exhibited inhibitory activity against all evaluated isoenzymes, with IC₅₀ values (µM) of 2.06 for CYP2A6, 6.17 for CYP2B6, 11.89 for CYP2D6, 6.37 for CYP2E1, and 2.36 for CYP3A4. MM/GBSA results supported a strong binding affinity of psilocin, driven by specific interactions with key amino acid residues within the active sites, including stabilizing hydrogen bonds.
Conclusions: These findings indicate that psilocin acts as a relevant inhibitor of multiple CYP450 isoenzymes, particularly CYP2A6 and CYP3A4, highlighting a potential risk for metabolic drug–drug interactions that should be considered in both clinical and toxicological contexts.